Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?
Techniques in Coloproctology · 2024
DOI: 10.1007/s10151-024-03027-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Techniques in Coloproctology, 2024. Verfasst von L Schabl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA. schabl.lukas@gmail.com. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Adenocarcinoma, Mucinous, Neoplasm Staging. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Austrian Society of Surgery.
Abstract (Originalsprache)
BACKGROUND: This study aimed to compare clinical outcomes of patients with clinical stage III mucinous rectal adenocarcinoma (M) and non-mucinous rectal adenocarcinoma (NM) and evaluate the effectiveness of neoadjuvant chemoradiation. It was hypothesized that patients with M would fare worse with neoadjuvant chemoradiation than those with NM and that patients with M and NM not receiving chemoradiation would have similar outcomes. Moreover, it was hypothesized that patients with M would have similar outcomes regardless of chemoradiation. METHODS: This study compares eligible patients distributed in three cohorts: (cohort 1) M versus NM, including only patients treated with neoadjuvant chemoradiation; (cohort 2) M versus NM, including only patients treated without neoadjuvant chemoradiation; and (cohort 3) only M patients treated with versus without neoadjuvant chemoradiation. RESULTS: We identified 515 patients with an average age of 58.8 (SD 12.4) years, and 30% were female. Fifty-seven (11.1%) patients had M and 458 (88.9%) had NM. Neoadjuvant chemoradiation was administered to 382 (74%) patients, of whom 41 (10.7%) were M and 341 (89.3%) NM. In cohort 1, patients with M had advanced pathological staging (stage 3: M 68% vs. NM 42%; p < 0.001), worse pathological differentiation (poor: M, 37% vs. NM, 11%; p = 0.001), more involved lymph nodes (M 0 [0;7] vs. NM 0 [0;1]; p < 0.001) and a higher rate of local recurrence (M 22% vs. 3%; p < 0.001). Patients with M demonstrated worse 7-year cancer-specific (p = 0.007) and overall survival (p = 0.01). There were no significant differences in cohort 2 and 3. CONCLUSION: Patients with clinical stage III mucinous adenocarcinomas may not benefit as much from standard neoadjuvant chemoradiation as their non-mucinous counterparts do.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department for Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA. schabl.lukas@gmail.com.
- Department for General Surgery, University Hospital of Salzburg, Salzburg, Austria. schabl.lukas@gmail.com.
- Department for Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
- Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Förderung
- Austrian Society of Surgery
Zitieren
APA
Schabl, L., Duraes, L. C., Connelly, T., Sancheti, H., Miller, J., Steele, S. R., & Kessler, H. (2024). Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?. Techniques in Coloproctology. https://doi.org/10.1007/s10151-024-03027-w
Vancouver
Schabl L, Duraes LC, Connelly T, Sancheti H, Miller J, Steele SR, et al. Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?. Techniques in Coloproctology. 2024. doi:10.1007/s10151-024-03027-w
BibTeX
@article{Schabl2024,
author = {Schabl, L and Duraes, L C and Connelly, T and Sancheti, H and Miller, J and Steele, S R and Kessler, H},
title = {Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?},
journal = {Techniques in Coloproctology},
year = {2024},
doi = {10.1007/s10151-024-03027-w}
}
EUVIMED